Psychemedics Corporation (PMD) |
| 2.67 2.67 (100%) 02-10 16:00 |
| Open: | 2.67 |
| High: | 2.67 |
| Low: | 2.67 |
| Volume: | 112,269 |
| Market Cap: | 16(M) |
| PE Ratio: | -5.24 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Medical - Diagnostics & Research |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 9.67 |
| Resistance 1: | 9.31 |
| Pivot price: | 9.00 |
| Support 1: | 8.73 |
| Support 2: | 7.26 |
| 52w High: | 2.67 |
| 52w Low: | 2.6 |
Established in 1986 and based in Acton, Massachusetts, Psychemedics Corporation specializes in providing comprehensive drug abuse detection services. The company operates across the United States, Brazil, and various international locations, employing hair sample analysis to identify a broad spectrum of substances. Their rigorous testing methodology involves both initial screening and confirmatory analysis through mass spectrometry, adhering to recognized industry standards. Psychemedics' analytical capabilities cover a wide array of drugs, including common illicit substances like cocaine, marijuana, and PCP. They also detect various amphetamines, such as ecstasy, eve, and Adderall, along with a comprehensive list of opiates, including heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine. Furthermore, their tests identify synthetic cannabinoids (e.g., K2, Spice, Blaze), benzodiazepines (like Xanax, Valium, and Ativan), nicotine, and Fentanyl. The results of their analyses offer more than just a positive or negative finding; they provide quantitative data indicating the approximate amount of drug consumed. Crucially, the tests also yield historical information that can reveal an individual's drug use patterns over an extended period. Psychemedics serves a diverse clientele, including employers seeking applicant and employee drug screening, treatment professionals, law enforcement agencies, school administrators, and parents concerned about potential substance use by their children.
| EPS | -0.650 |
| Book Value | 11.770 |
| PEG Ratio | 16.74 |
| Gross Profit | 2.731 |
| Profit Margin (%) | -14.18 |
| Operating Margin (%) | 14.28 |
| Return on Assets (ttm) | 1.2 |
| Return on Equity (ttm) | -5.3 |
Tue, 22 Sep 2026
Psychemedics Corporation stock holds at a dated market level - AD HOC NEWS
Thu, 30 Apr 2026
Psychemedics Corporation Releases 2026 Workforce Insights Report Revealing Key Drug Trends and Implications for Workplace Safety - Quiver Quantitative
Thu, 24 Apr 2025
Psychemedics Corporation (PMD) Stock Price, News & Analysis - Stock Titan
Sat, 14 Dec 2024
Psychemedics (OTCPK:PMDI) - Stock Analysis - Simply Wall Street
Thu, 12 Dec 2024
Psychemedics sees significant stock acquisition by investment group By Investing.com - Investing.com
Thu, 05 Dec 2024
Psychemedics corp director Peter Kamin purchases $3.31m in stock - Investing.com
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |